The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

NCT ID: NCT00227357

Last Updated: 2010-06-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

101 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-07-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to develop and evaluate an innovative model of care to better serve patients who are both HIV-infected and opioid-dependent.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypothesis: HIV, opioid dependent patients provided agonist therapy at the site of their primary care will have better retention, utilization of services, health, social and quality of care measures and psychiatric treatment outcomes.

The Buprenorphine Project is an examination of two methods of service delivery. The purpose of this study is to assess the feasibility, cost and effectiveness of an intervention designed to integrate buprenorphine treatment for opioid dependence into HIV primary care at the CORE Center. For this project we will provide buprenorphine to 60 opioid dependent patients at any one time and will compare this on-site treatment group to 60 opioid dependent HIV+ patients who select off-site methadone or no agonist treatment at the time of enrollment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections AIDS Opiate Dependence Post-Traumatic Stress Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Buprenorphine

Study patients receiving buprenorphine treatment

On-site - buprenorphine/naloxone (Suboxone)

Intervention Type DRUG

Tablet, sub-lingual, 8/2 mg, 1-3 daily

Comparison

Study patients receiving methadone or no agonist treatment

Off-site - methadone or no agonist

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

On-site - buprenorphine/naloxone (Suboxone)

Tablet, sub-lingual, 8/2 mg, 1-3 daily

Intervention Type DRUG

Off-site - methadone or no agonist

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older
* Patient of the CORE Center
* HIV-infected (confirmed by HIV assay results)
* Opioid-dependent (by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision \[DSM-IV-TR\] criteria)
* Fluent in English or Spanish
* Planning to stay in Chicago area for the next 12 months

Exclusion Criteria

* Liver function tests (LFTs) (transaminase only) at 5 times or higher than normal
* DSM-IV-TR criteria for benzodiazepine abuse or dependence within the past 6 months
* DSM-IV-TR criteria for alcohol dependence within the past 6 months or actively suicidal
* Psychiatric impairment that impedes ability to consent
* Methadone dose exceeds level allowing for safe transition to buprenorphine
* Pregnant women or women actively trying to become pregnant
* Clinical judgement that patient is inappropriate for medical or psychiatric reasons
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Health Resources and Services Administration (HRSA)

FED

Sponsor Role collaborator

The New York Academy of Medicine

OTHER

Sponsor Role collaborator

Ruth M. Rothstein CORE Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

The Ruth M. Rothstein CORE Center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffrey D. Watts, M.D.

Role: PRINCIPAL_INVESTIGATOR

The CORE Center and John H. Stroger, Jr. Hospital of Cook County, Affiliates of the Cook County Bureau of Health Services

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The CORE Center

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.corecenter.org

Click here for more information about The CORE Center.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1-H97HA03796-01-00

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prescribe to Save Lives
NCT03175640 COMPLETED NA